Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
ALFA Filings
Every announcement, straight from the exchange
Every Laurus Labs results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements with these filters
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.
Laurus Labs announced its FY26 results, reporting ₹6,813 Crore in revenue with a 23% year-on-year growth. EBITDA reached ₹1,826 Crore with 26.8% margins, driven by strong CDMO performance and a better product mix. The company declared a second interim dividend of ₹1.2 per share and continues major CAPEX investments for future growth.